Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Shift Work Schedule, Circadian Rhythm, I...
Phase PHASE4
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to examine the impact of timed cortisol release or differently timed cortisol rhythms on insulin resistance in both men and women undergoing sleep restriction. Chronic sleep loss is highly prevalent, affecting 1 in 3 adults in the US. Chronic sleep loss causes stress which induces insulin resistance and leads to obesity and type 2 diabetes. Many factors contribute to sleep loss including shift work, environmental disturbances, sleep/circadian disorders and comorbid medical and mental health conditions. Sleep loss increases the stress hormone cortisol in the evening and decreases daytime testosterone. Examining these hormones in a controlled laboratory environment under different sleep schedules may help researchers find solutions for adults experiencing negative health consequences related to chronic sleep loss.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: Double

Interventions / Regimen

  • Drug: Metyrapone And Hydrocortisone — Cortisol will be clamped with oral administration of Metyrapone, which blocks endogenous cortisol biosynthesis. A loading dose of 3,000mg will be given at 10:00 on day 2. Every 4 hours throughout the sleep restriction and sleep deprivation phases, 500mg will be administered beginning at 14:00 on day 2 and ending with a dose at 18:00 on day 5. Using a subcutaneous pump, hydrocortisone is administered here as physiological replacement, with pulses every 3 hours beginning at 10:00 on day 2. Participants will receive 3 tiers of doses: low (0.5mg), moderate (2.3mg) and high (4.0mg), the timing of which is specified by their condition assignment. For all participants, an oral 25mg dose of hydrocortisone will be given at the end of the constant routine period to prevent any future hypocortisolemia associated with the hormone clamp.
  • Drug: Dextrose — The frequently sampled intravenous glucose tolerance test is performed before and after sleep restriction, and is widely used and validated. This procedure requires intravenous administration of dextrose, 300 mg/kg as a bolus at time zero. Insulin (0.03 units/kg/min) will be slowly infused intravenously over a 5 minute period from 20 to 25 minutes. Few side effects are anticipated as both doses of glucose and insulin should result in a high, but physiological peak. Administration of insulin as 5-min infusion for clinical studies (rather than bolus) reduces the max concentrations achieved. It is not uncommon for glucose to dip below fasting glycemia at some point after the insulin administration. The concentration at the nadir depends on the subject's insulin sensitivity. Return to fasting level is a function of the waning of the insulin effect (incorporated into the minimal model) as well as counterregulation (which depends on the concentration at the nadir). This can be addressed,
  • Drug: insulin — The frequently sampled intravenous glucose tolerance test is performed before and after sleep restriction, and is widely used and validated. This procedure requires intravenous administration of dextrose, 300 mg/kg as a bolus at time zero. Insulin (0.03 units/kg/min) will be slowly infused intravenously over a 5 minute period from 20 to 25 minutes. Few side effects are anticipated as both doses of glucose and insulin should result in a high, but physiological peak. Administration of insulin as 5-min infusion for clinical studies (rather than bolus) reduces the max concentrations achieved. It is not uncommon for glucose to dip below fasting glycemia at some point after the insulin administration. The concentration at the nadir depends on the subject's insulin sensitivity. Return to fasting level is a function of the waning of the insulin effect (incorporated into the minimal model) as well as counterregulation (which depends on the concentration at the nadir). This can be addressed,

Primary Outcomes

  • Insulin resistance-Minimal Model (Si) (Change from baseline collection.)
  • Insulin Resistance-Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) (Change from baseline collection.)
  • Insulin Resistance-Insulin Sensitivity Index (Mi) (Change from baseline collection.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-07-16
Completion: 2029-07
Eligibility
Age: 18 Years – 45 Years
Sex: ALL
Volunteers: true
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Washington State University
Collaborators: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Principal Investigators:
  • Peter Liu, MBBS, PhD (PRINCIPAL_INVESTIGATOR) - Lundquist Institute of Biomedical Innovation at Harbor-UCLA Medical Center
  • Hans P.A. Van Dongen, PhD (PRINCIPAL_INVESTIGATOR) - Washington State University
Contact Information
Study Contact:
Devon A Hansen, PhD
509-358-7754
devon.hansen@wsu.edu
Olivia Brooks, MS
509-358-7904
olivia.brooks@wsu.edu
Olivia Brooks, MS
509-358-7750
olivia.brooks@wsu.edu
Sleep and Performance Research Center
Interventions
  • Drug: Metyrapone And Hydrocortisone — Cortisol will be clamped with oral administration of Metyrapone, which blocks endogenous cortisol biosynthesis. A loading dose of 3,000mg will be given at 10:00 on day 2. Every 4 hours throughout the sleep restriction and sleep deprivation phases, 500mg will be administered beginning at 14:00 on day 2 and ending with a dose at 18:00 on day 5. Using a subcutaneous pump, hydrocortisone is administered here as physiological replacement, with pulses every 3 hours beginning at 10:00 on day 2. Participants will receive 3 tiers of doses: low (0.5mg), moderate (2.3mg) and high (4.0mg), the timing of which is specified by their condition assignment. For all participants, an oral 25mg dose of hydrocortisone will be given at the end of the constant routine period to prevent any future hypocortisolemia associated with the hormone clamp.
  • Drug: Dextrose — The frequently sampled intravenous glucose tolerance test is performed before and after sleep restriction, and is widely used and validated. This procedure requires intravenous administration of dextrose, 300 mg/kg as a bolus at time zero. Insulin (0.03 units/kg/min) will be slowly infused intravenously over a 5 minute period from 20 to 25 minutes. Few side effects are anticipated as both doses of glucose and insulin should result in a high, but physiological peak. Administration of insulin as 5-min infusion for clinical studies (rather than bolus) reduces the max concentrations achieved. It is not uncommon for glucose to dip below fasting glycemia at some point after the insulin administration. The concentration at the nadir depends on the subject's insulin sensitivity. Return to fasting level is a function of the waning of the insulin effect (incorporated into the minimal model) as well as counterregulation (which depends on the concentration at the nadir). This can be addressed,
  • Drug: insulin — The frequently sampled intravenous glucose tolerance test is performed before and after sleep restriction, and is widely used and validated. This procedure requires intravenous administration of dextrose, 300 mg/kg as a bolus at time zero. Insulin (0.03 units/kg/min) will be slowly infused intravenously over a 5 minute period from 20 to 25 minutes. Few side effects are anticipated as both doses of glucose and insulin should result in a high, but physiological peak. Administration of insulin as 5-min infusion for clinical studies (rather than bolus) reduces the max concentrations achieved. It is not uncommon for glucose to dip below fasting glycemia at some point after the insulin administration. The concentration at the nadir depends on the subject's insulin sensitivity. Return to fasting level is a function of the waning of the insulin effect (incorporated into the minimal model) as well as counterregulation (which depends on the concentration at the nadir). This can be addressed,
Study Locations (1 sites)
Sleep and Performance Research Center, Spokane, Washington 99202 United States
Eligibility Criteria
Inclusion Criteria: 1. Must be between 18-45 years old. 2. Has a BMI of 18-25 kg/m2 stable weight over the previous 6 weeks. 3. Is physically and psychologically healthy (incl. regular menstrual cycles in women, no clinical disorders and/or illnesses). Women will be studied during the follicular phase of their menstrual cycle. Menstrual cycle criteria (using PMID 10941950) 18 to 25 years - Cycle variation ≤9 days 26 to 41 years - Cycle variation ≤7 days 42 to 45 years - Cycle variation ≤9 days 4. No current medical or drug treatment (to include steroids or hormones of any type including contraceptives), as assessed by questionnaire. 5. Has a negative pregnancy test (women), no clinically significant abnormalities in blood and urine, and free of traces of drugs. 6. No history of clinically relevant psychiatric illness. 7. No previous history of drug or alcohol abuse. 8. Not a current smoker. 9. No history of brain injury or of learning disability. 10. No previous adverse reaction to sleep deprivation, jet lag, shift work or any of the drugs to be administered. 11. Not vision or hearing impairment unless corrected back to normal. 12. No endocrine disorder (no abnormal thyroid function tests; no abnormal morning blood cortisol; no primary gonadal disease as indicated by serum LH or FSH concentration \> 10 or \> 15 IU/L, respectively; and no hyperprolactinemia indicated by prolactin \> 25 μg/L). 13. No sleep or circadian disorder. 14. Has good habitual sleep with regular bedtimes (between 6 and 10 hours in duration). 15. Not extreme morning- nor extreme evening-type using Horne-Ostberg Morningness-Eveningness criteria. 16. No travel across time zones within one month of entering the study. 17. No shift work within three months of entering the study. 18. No anemia (hematocrit \<38% in men, \<34% in women). 19. No blood donation within the previous 8 weeks. 20. No concurrent participation in another research study.
Conditions Bariatric Surgery, Type 2 Diabetes
Phase PHASE3
Enrollment 54
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Obesity progresses worldwide with few effective treatments leading to a burst in Bariatric surgery (BS). France is the 3rd country in BS numbers yearly. BS improves diabetes (T2D) and even induces diabetes remission (DR) in 60% of patients. Thus, an expert consensus recommended extending BS to T2D with BMI≥30kg/m² with uncontrolled glycaemia, anticipating even more BS. Glycaemic control further deteriorates in the longer term in non DR (NDR) patients and relapse occurs in some DR patients, urging the need to add new therapy to control glycaemia and provide new recommendations in the future. Obesity and T2D are characterized by gut microbiota dysbiosis with low to very low microbial gene richness (MGR). About 75% of patients' candidates for BS are in the low MGR category. Whereas BS modifies microbiota composition and increases MGR 1-year post-BS, we demonstrated that only a few patients reach high MGR. Dysbiosis can be improved by several means; fibre enriched diet, prebiotics, probiotics also improve metabolic alterations and insulin resistance in mice. However, human studies observed rather divergent results: some studies display a beneficial effect in improving insulin-resistance but to a small extent while others do not display any significant effects at all. Therefore, other innovative strategies should be tested in humans. For example, Faecal microbiota transfer (FMT) ameliorates insulin sensitivity and MGR in metabolic syndrome patients, but was never tested in T2D nor post-BS. Whether adding such an innovative therapy to further modify gut microbiota post-BS can help improve glucose control should be tested. FMT showed health benefits in several diseases (clostridium difficile (CD) and Crohn's). Until recently, FMT was performed using invasive tool (endoscopy or colonoscopy) thus with potential secondary effects, or enema yet maybe less effective. Recent technologic developments enabled to generate oral capsulized FMT (filled with fecal material) performing as well as invasive FMT for CD with good tolerance. This strategy has never been tested in obesity or T2D, whereas in metabolic syndrome patients (before T2D occurrence) and less severe dysbiosis, a proof-of-concept study showed that endoscopic FMT may improve insulin sensitivity after 6 weeks. Yet these studies have included a small number of patients, non T2D and did not test oral FMT. We here hypothesize that an intervention improving dysbiosis after 1-year post-BS might help improve/maintain diabetes control in the long-term. We will examine the effects of FMT (from lean healthy donors) vs. placebo transfer in dietary-controlled non-DR patients after 1-year post-BS, on Hba1c reduction evaluated 6 months' post-intervention

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution — 1 FMT=30 capsulized FMT given during 2 days in several intakes per day (3 intakes per day). FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%.
  • Drug: Capsulized placebo transfer containing dilution solution — 1 Placebo of FMT=30 capsulized given during 2 days in several intakes per day (3 intakes per day). Placebo of FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%.

Primary Outcomes

  • Hba1c change from baseline to 6 months post randomization (At baseline and at 6 months after randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-01-21
Completion: 2029-02
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 54 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Contact Information
Study Contact:
Judith Aron-Wisnewsky, Pr
+33 1 42 17 75 41
judith.aron-wisnewsky@aphp.fr
Karine Clement, Pr
+33 1 42 17 79 28
karine.clement@aphp.fr
Judith Aron-Wisnewsky, Pr
+33 1 42 17 75 41
judith.aron-wisnewsky@aphp.fr
Groupe hospitalier Pitié-Salpêtrière
Interventions
  • Drug: Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution — 1 FMT=30 capsulized FMT given during 2 days in several intakes per day (3 intakes per day). FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%.
  • Drug: Capsulized placebo transfer containing dilution solution — 1 Placebo of FMT=30 capsulized given during 2 days in several intakes per day (3 intakes per day). Placebo of FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%.
Study Locations (1 sites)
Groupe hospitalier Pitié-Salpêtrière, Paris, 75013 France
Eligibility Criteria
Inclusion Criteria patients : * Adult patients from 18-65 years old * T2D patients any severity of initial T2D disease before BS * Who underwent Bariatric surgery (BS) 1 to 5 years before (Roux-en-Y gastric bypass or sleeve, patients with pre-BS BMI≥35kg/m²) * Non-Diabetic remission (NDR) patients 1-year post-BS, defined as Hba1c\>6.5% and/or fasting glycaemia\>6.9mmol/l and/or receiving anti-diabetic drugs for at least 2 months. We will rather select patients with uncontrolled diabetes with Hba1c\>7% and willing to receive proton pump inhibitor (PPI) * Patient compliant to 1rd year follow-up post-BS (who came to at least 2 among the three routine care follow-up visits during the first year (i.e. 3, 6 and 12M) * Signature of the informed consent * Affiliated to a social security regime (except AME) Exclusion Criteria patients : * Type 1 diabetes * Patients receiving antibiotics (ATB) at the selection time or within the 3 previous months (if agreeing to participate to the study, the patients will be proposed randomization 3 months after stopping ATB) * Immunosuppressive therapy * Laxative treatments * DR since BS (nor relapse patients detailed further in the protocol) * Patients already recruited in another interventional studies study where a drug is being tested * Pregnant or breastfeeding women * Patient with contemporary disease such as intestine disease * Patient under guardianship or curatorship * Patient deprived of their liberty by a judicial or administrative decision Inclusion criteria donors: * Age ≥ 18 years and \< 50 years * Lean individuals (18\<BMI\<25kg/m²) * Euglycemic: fasting glycemia \<6mmol/l; Hba1c \<5.9% * Healthy: no current drug prescription (except contraception or pain killers other than AINS) * Regular bowel movement in the morning defined as 1 stool/day at least * Signature of the informed consent * Subject with health insurance (except AME) Exclusion criteria donors: * Familial history of obesity or diabetes and personal history of overweight/obesity * Infectious risk * Gastrointestinal disease * Exclusion criteria according screening test to National Agency for the Safety of Medicines and Health Products (ANSM) recommendations * Pregnancy or breastfeeding women * Subject under guardianship or curatorship * Subject deprived of their liberty by a judicial or administrative decision
Conditions Weight Management
Phase PHASE1
Enrollment 134
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2 Diabetes Mellitus (T2DM). The primary objectives of this study are: * To characterize the pharmacokinetics (PK) of GS-4571 following single and multiple ascending oral doses of GS-4571. * To evaluate the effect of concomitant food intake and (if conducted) a representative acid-reducing agent (proton pump inhibitor (PPI), omeprazole) on the PK of GS-4571. * To evaluate the safety and tolerability of single and multiple ascending oral doses of GS-4571.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: GS-4571 — Administered orally
  • Drug: Placebo — Administered orally
  • Drug: Omeprazole — Administered orally

Primary Outcomes

  • Single-Dose PK Parameter AUCinf of GS-4571 (Up to 96 hours postdose)
  • Single-Dose PK Parameter Cmax of GS-4571 (Up to 96 hours postdose)
  • Multiple-Dose Plasma PK Parameter: AUCtau of GS-4571 (Up to 96 hours postdose)
  • Multiple-Dose Plasma PK Parameter: Cmax of GS-4571 (Up to 96 hours postdose)
  • Percentage of Participants of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Deaths (Day 1 up to 95 days)
  • Percentage of Participants of Treatment-Emergent Laboratory Abnormalities (Day 1 up to 95 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-08-28
Completion: 2027-02
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 134 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gilead Sciences
Principal Investigators:
  • Gilead Study Director (STUDY_DIRECTOR) - Gilead Sciences
Contact Information
Study Contact:
Gilead Clinical Study Information Center
1-833-445-3230 (GILEAD-0)
GileadClinicalTrials@gilead.com
Interventions
  • Drug: GS-4571 — Administered orally
  • Drug: Placebo — Administered orally
  • Drug: Omeprazole — Administered orally
Study Locations (3 sites)
Qps-Mra, Llc., Miami, Florida 33143 United States
ICON Early Phase Services, LLC, San Antonio, Texas 78232 United States
ICON, Salt Lake City, Utah 84124 United States
Eligibility Criteria
Key Inclusion Criteria: * Age 18 through 55 years, for Parts A, B, and C, and 18 through 65 years, for Part D. * Individuals must be glucagon-like peptide-1 receptor agonist (GLP-1RA) naïve OR last dose was at least 6 months prior to screening. * Part A (SAD) and Part B (Food/PPI Effect): eligible individuals in Cohorts 1-4, (optional cohort 5) and 6 will include healthy individuals with BMI of ≥ 19 and \< 30 kg/m\^2, and no significant medical history. Individuals will also be in good general health as determined by the investigator at the screening evaluation performed no more than 28 days prior to the scheduled first dose. * Part C (MAD in nondiabetic obese individuals): Eligible individuals in Cohorts 7-9 and (optional cohort 10) will be individuals with obesity with BMI ≥ 30 kg/m\^2 and \< 45 kg/m\^2 with a total body weight \> 50 kg, and nondiabetic (HbA1c \< 6.5%). Eligible individuals will also be individuals with stable body weight (\< 5% change) for 90 days prior to screening visit based on individual report. * Part D (multiple doses in non-obese T2DM): eligible individuals in Cohort 11 will be individuals with T2DM HbA1c ≥ 7.0% and ≤ 10.5% with BMI of ≥ 19 and \< 30 kg/m\^2 and treated with diet and/or exercise, and/or metformin monotherapy. Key Exclusion Criteria: * Have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with individual treatment, assessment, or compliance with the protocol. This would include acute pancreatitis, or history of pancreatitis, acute gallbladder disease, and renal, cardiac, hematological, hepatic, pulmonary (including chronic asthma), endocrine (including diabetes \[with the exception of T2DM for individuals included in Part D only\]), central nervous, gastrointestinal (including an ulcer), vascular, metabolic (thyroid disorders, adrenal disease), immunodeficiency disorders, active infection, or malignancy that are clinically significant or requiring treatment. * Current symptoms of diabetic retinopathy or examination indicating diabetic retinopathy within one year of screening. * Any electrolyte disturbances identified at screening considered to be clinically significant in the opinion of the investigator (eg, hypokalemia, hypocalcemia, or hypomagnesemia). * Any condition that could lead to electrolyte disturbances (eg, eating disorder) in the opinion of the investigator. * History of syncope, palpitations, or unexplained dizziness. * Active, or history of, significant cardiac disease or conduction abnormality * History of implanted defibrillator or pacemaker. * Have been treated with the following within 6 months prior to screening or is expected to receive these agents during the study: GLP-1RAs, systemic steroids, immunosuppressant therapies, or chemotherapeutic agents (eg, corticosteroids, immunoglobulins, other immune or cytokine-based therapies). * Previously stopped use of GLP-1RAs secondary to severe side effects including nausea, constipation, diarrhea, or emesis. Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Conditions Asthma
Phase PHASE2
Enrollment 531
Locations 119 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Brenipatide — Administered SC
  • Drug: Brenipatide — Administered SC
  • Drug: Placebo — Administered SC

Primary Outcomes

  • Annualized Asthma Exacerbation Rate Over 52 Weeks of Treatment (Baseline to Week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-10-22
Completion: 2028-06
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 531 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eli Lilly and Company
Principal Investigators:
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-45 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (STUDY_DIRECTOR) - Eli Lilly and Company
Contact Information
Study Contact:
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
317-615-4559
LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
602-910-3343
AMR Clinical
Interventions
  • Drug: Brenipatide — Administered SC
  • Drug: Brenipatide — Administered SC
  • Drug: Placebo — Administered SC
Study Locations (119 sites)
AMR Clinical, Tempe, Arizona 85281 United States
NewportNativeMD, Inc., Newport Beach, California 92663 United States
California Medical Research Associates, Northridge, California 91324 United States
Peninsula Research Associates, Rolling Hills Estates, California 90274 United States
Asthma & Allergy Associates - Colorado Springs, Colorado Springs, Colorado 80907 United States
AMR Clinical, Doral, Florida 33172-2514 United States
Renstar Medical Research, Ocala, Florida 34470 United States
Avanza Medical Research Center, Pensacola, Florida 32503 United States
USF Health, Tampa, Florida 33613 United States
Axis Clinical Trials - Westchester, Westchester, Illinois 60154 United States
Eligibility Criteria
Inclusion Criteria: * Physician-diagnosed asthma who have received a physician-prescribed asthma controller medication for at least 12 months prior to screening visit. * Participants must have an asthma control questionnaire-6 (ACQ-6) score of ≥1.5 on 2 out of 3 visits before randomization. * History of 1 severe asthma exacerbation that led to systemic glucocorticoid treatment in the last 12 months prior to screening visit. Exclusion Criteria: * Participants are excluded from the study if any of the following criteria apply: * An established diagnosis of occupational asthma * Known pre-existing, clinically important lung condition other than asthma, including but not limited to: * chronic respiratory infection * bronchiectasis * pulmonary fibrosis * allergic bronchopulmonary aspergillosis * emphysema * chronic bronchitis * eosinophilic granulomatosis with polyangiitis * chronic obstructive pulmonary disease, and * other mimics of asthma, that is, vocal cord dysfunction. * Have a current or recent acute, active infection. For at least 30 days before screening visit and up to the randomization visit.
Conditions Asthma, Respiratory Tract Infections, Ga...
Phase PHASE3
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The overall aim of the study is to develop a nutritional preventive vitamin D supplementation strategy in pregnancy for early childhood asthma/persistent wheeze during the first three years of life as we hypothesize that supplementation in higher doses than recommended could reduce the risk of disease development.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Cholecalciferol D3 — Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
  • Other: Olive oil — Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery

Primary Outcomes

  • Early childhood asthma/persistent wheeze age 0-3 years (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-12-20
Completion: 2033-03
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: true
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Professor Klaus Bønnelykke
Principal Investigators:
  • Klaus Bønnelykke, PhD (PRINCIPAL_INVESTIGATOR) - Copenhagen Studies on Asthma in Childhood
  • Bo Chawes, PhD (PRINCIPAL_INVESTIGATOR) - Copenhagen Studies on Asthma in Childhood
Contact Information
Study Contact:
Klaus Bønnelykke, PhD
+4538677360
kb@copsac.com
Ulrik Ralfkiaer, PhD
+4538674164
administration@dbac.dk
Klaus Bønnelykke, PhD
+4538677360
kb@copsac.com
Copenhagen University Hospital of Copenhagen
Interventions
  • Dietary Supplement: Cholecalciferol D3 — Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
  • Other: Olive oil — Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
Study Locations (1 sites)
Copenhagen University Hospital of Copenhagen, Gentofte Municipality, DK-2820 Denmark
Eligibility Criteria
* Pregnant Danish women before week 26 with blood levels of EPA+DHA above 4.7% of total fatty acids * No current vitamin D intake above the recommended 400 IU/day * No endocrine-, heart-, kidney- or auto-immune disorders * No disorders requiring treatment with blood thinning medication
Conditions Chronic Rhinosinusitis With Nasal Polyps...
Phase PHASE1, PHASE2
Enrollment 64
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This study is a randomized, double-Blind, placebo-controlled, Single and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with or without Asthma.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: BBT002 — BBT002 will be administered.
  • Drug: Placebo — Placebo will be administered

Primary Outcomes

  • Number of participants with adverse events following single and multiple administration of BBT002 (Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration)
  • Number of participants with change in vital sign measurements following dose administration. (Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration)
  • Number of participants with change in physical examination following dose administration. (Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration)
  • Number of participants with change in Laboratory assessments (Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration)
  • Number of participants with change in 12-lead ECG readings (Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-03-02
Completion: 2028-06-30
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bambusa Therapeutics
Contact Information
Study Contact:
Tracy Ji, Senior study Director
+86 18001322760
Tracy.Ji@bambusatx.com
Min Wang
010-88325988
rmyyyljd@163.com
People's Hospital of Peking University
Min Wang
People's Hospital of Peking University
Interventions
  • Drug: BBT002 — BBT002 will be administered.
  • Drug: Placebo — Placebo will be administered
Study Locations (12 sites)
People's Hospital of Peking University, Beijing, Beijing Municipality 100044 China
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630 China
Xiangya Hospital of Central South University, Changsha, Hunan 410008 China
Jiangsu Province Hospital, Nanjing, Jiangsu 210029 China
The Second Hospital of Shandong Province, Jinan, Shandong 250022 China
Qingdao University Hospital, Qingdao, Shandong 266003 China
The Affiliated Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000 China
Zibo Hospital of Shandong University, Zibo, Shandong 255036 China
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality 200127 China
The Second Hospital of Chengdu City, Chengdu, Sichuang 610017 China
Eligibility Criteria
Inclusion Criteria: Part (A\&B): 1. Age of 18-55 years (HVs), 18-75 years (patients) 2. Body mass index between 18-30 kg/m², capped at 120 kg 3. Negative pregnancy tests for women of childbearing potential 4. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit 5. Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex smokers Key Inclusion Criteria (Part B only) 1. Participants with physician-diagnosed CRSwNP before screening. 2. SNOT-22 total score ≥30 at screening and randomization. 3. Documented systemic corticosteroid use (or contraindication/intolerance) within past 24 months. 4. Diagnosed asthma per GINA 2025, stable for ≥12 months. Stable on GINA Step 3 or higher therapy for 6 weeks before screening. 5. For the participants have comorbid asthma, they had to be stable using their regular asthma treatment. Exclusion Criteria:Part (A\&B): 1. Positive viral serology for human immunodeficiency virus (HlV), hepatitis C virus (HCV), or hepatitis B (HBV) 2. Immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections 3. History of major metabolic, dermatological, liver, kidney, hematological or other significant disorders 4. Clinically relevant abnormal lab results, including low blood counts, liver enzymes, or abnormal kidney function 5. Positive drug/alcohol tests or abnormal vital signs at screening or Day -1 6. Abnormal Electrocardiogram(ECG) findings 7. History of drug/alcohol abuse in the past 2 years 8. History of severe allergic reactions or hypersensitivity Key Exclusion Criteria for (Part B only): 1. Any sinus/nasal surgery (including polypectomy) within 6 months before screening, History of \>2 prior sinus/nasal surgeries 2. Concurrent nasal conditions that may interfere with study assessments 3. Significant or unstable cardiovascular diseases 4. Recent clinically significant infection
Conditions COPD, Asthma
Phase NA
Enrollment 420
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Our research group has found that Canadians with undiagnosed asthma or chronic obstructive pulmonary disease (COPD) have increased respiratory symptoms and worse health-related quality of life. The investigators recently developed and validated an on-line questionnaire to accurately identify these symptomatic, undiagnosed individuals. The investigators will advertise in the community asking individuals to complete the on-line questionnaire at home, at their leisure, to determine if they are at risk of asthma or COPD. Those at risk will be invited to participate in a randomized, controlled clinical trial to determine whether early diagnosis of previously undiagnosed asthma or COPD and subsequent treatment by the primary care practitioner will improve their quality of life.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: Single

Interventions / Regimen

  • Other: Early diagnosis and treatment — Early diagnosis of previously undiagnosed asthma or COPD and subsequent treatment by a primary care practitioner

Primary Outcomes

  • Change in disease-specific quality of life quantified using the St. George's Respiratory Questionnaire (SGRQ). (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-16
Completion: 2029-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 420 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ottawa Hospital Research Institute
Principal Investigators:
  • Shawn Aaron, MD (PRINCIPAL_INVESTIGATOR) - Ottawa Hospital Research Institute
Contact Information
Study Contact:
Shawn Aaron, MD
6137378259
saaron@toh.ca
Kathy Vandemheen, MScN
6137378259
kvandemheen@toh.ca
Andrew McIvor, MD
St. Joseph's Hamilton Healthcare
Interventions
  • Other: Early diagnosis and treatment — Early diagnosis of previously undiagnosed asthma or COPD and subsequent treatment by a primary care practitioner
Study Locations (6 sites)
St. Joseph's Hamilton Healthcare, Hamilton, Ontario L8N 4A6 Canada
Kingston Health Sciences Centre/Queen's University, Kingston, Ontario K7L 2V6 Canada
Ottawa Hospital General Campus, Ottawa, Ontario K1H 8L6 Canada
St. Michael's Hospital/Unity Health Toronto, Toronto, Ontario Canada
Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Quebec G1V 4G5 Canada
Royal University Hospital, Saskatoon, Saskatchewan Canada
Eligibility Criteria
Inclusion Criteria: * Individuals at least 18 years old * Individuals must be symptomatic with respiratory symptoms * Individuals must complete the UCAP-Q questionnaire and score a ≥ 6% probability of having either asthma or COPD. * Individuals who have given written informed consent to participate in this trial in accordance with local regulations; * Individual must be able to perform pre and post bronchodilator spirometry to measure lung function Additional Inclusion Criteria for the Randomized Controlled Trial (RCT): * Individuals who have undiagnosed airflow obstruction on spirometry testing (i.e. Asthma or COPD) will be asked to participate in the RCT. Exclusion Criteria: * Individuals who report a previous diagnosis of asthma, COPD, history of lung cancer, bronchiectasis, interstitial lung disease, cystic fibrosis or other significant diagnosed lung disease. * Individuals currently under the care of a Respirologist. * Individuals currently using inhaled corticosteroids or long-acting bronchodilators. * Individuals with history of myocardial infarction, stroke, aortic or cerebral aneurysm, or detached retina or eye surgery within the past 3 months (spirometry is contraindicated) * Individuals who are in the third trimester of pregnancy * Individuals involved in another interventional trial
Conditions Bronchial Asthma
Phase PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Inhalation Aerosol in patients with bronchial asthma.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days — PA9159 of 60 μg is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.
  • Drug: PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days — PA9159 of 120 μg is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.
  • Drug: PA9159 Metered-Dose Inhaler, 240 μg per day for 28 days — PA9159 of 240 μg is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.
  • Drug: Placebo Metered-Dose Inhaler without PA9159, Twice daily for 28 days — Placebo is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.

Primary Outcomes

  • Evaluation the change in morning pre-dose forced expiratory volume in one second (FEV1) from baseline to week 4 of treatment. (From pre-dose until 28 days post-dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-02-24
Completion: 2026-03
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Anhui Palo Alto Pharmaceuticals, Inc.
Principal Investigators:
  • Wei Zuo (PRINCIPAL_INVESTIGATOR) - The First Affiliated Hospital of Nanchang University
Contact Information
Study Contact:
Mengli Kan
86-15618775927
kanmengli@paloaltopharma.com
Chunping Lu
86-15921612878
luchunping@paloaltopharma.com
Wei Zuo
86-15879098337
11545394@qq.com
The First Affiliated Hospital of Nanchang University
Interventions
  • Drug: PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days — PA9159 of 60 μg is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.
  • Drug: PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days — PA9159 of 120 μg is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.
  • Drug: PA9159 Metered-Dose Inhaler, 240 μg per day for 28 days — PA9159 of 240 μg is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.
  • Drug: Placebo Metered-Dose Inhaler without PA9159, Twice daily for 28 days — Placebo is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.
Study Locations (1 sites)
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006 China
Eligibility Criteria
Inclusion Criteria: * Aged 18 to 75 years inclusive, regardless of gender; * According to the definition in the Chinese "Guidelines for Prevention and Treatment of Bronchial Asthma (2020 Edition)," subjects diagnosed with bronchial asthma, including those with an initial diagnosis of asthma, or those diagnosed with asthma during childhood or adolescence with stable condition who have not received long-term treatment but exhibit significantly more pronounced symptoms in adulthood and/or recently compared to the past; * Pre-randomization, pulmonary function tests show 60% ≤ FEV1% predicted ≤ 85%; * Any objective test result indicating variable airflow limitation conducted within 1 year prior to screening is positive, or the bronchodilator test during the screening period is positive, i.e., an increase in FEV1 ≥ 12% and an absolute increase in FEV1 ≥ 200 mL 15-30 minutes after inhaling 400 μg salbutamol (if the bronchodilator test result does not meet the positive threshold, a repeat bronchodilator test is allowed within 14 days after the test \[excluding the test day\]); or the bronchial provocation test is positive, i.e., a decrease in FEV1 ≥ 20% after inhaling a provocant (methacholine or histamine); or the average daily diurnal variability of peak expiratory flow (PEF) (calculated as the sum of daily PEF diurnal variability over 7 consecutive days divided by 7) \> 10%; * Voluntarily sign the informed consent form. Exclusion Criteria: * Subjects who are unable to correctly use a nebulizer, cannot tolerate nebulized inhalation administration, or fail inhalation administration training; * Subjects with other pulmonary diseases, including chronic obstructive pulmonary disease, bronchiectasis, pulmonary fibrosis, tuberculosis, etc., for which, in the investigator's judgment, asthma remains the dominant condition; * Coexistence of other clinically significant conditions that may affect lung function, including but not limited to pleural diseases, mediastinal diseases, diaphragmatic disorders, myasthenia, thoracic deformities, etc.; * History of severe cardiovascular diseases, such as congestive heart failure, coronary artery disease, myocardial infarction, arrhythmia, uncontrolled hypertension (resting seated systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg on two or more consecutive measurements), etc., which, in the investigator's judgment, would put the subject at risk or may affect the interpretation of study results; * Subjects with hyperthyroidism, assessed by the investigator as unsuitable for participation in this trial; * History of severe hematologic, hepatic, psychiatric, renal, or other diseases that, in the investigator's judgment, would put the subject at risk or may affect the interpretation of study results; * History of malignancy within the past five years (excluding cured cervical intraepithelial neoplasia, thyroid cancer, or basal cell carcinoma of the skin diagnosed and cured within 5 years); * Subjects who have undergone or are expected to undergo solid organ or bone marrow transplantation within the next year; * Hypokalemia (serum potassium \< 3.5 mmol/L during screening); * Type I diabetes or poorly controlled Type II diabetes (fasting blood glucose \> 11.1 mmol/L during screening); * Known or pre-randomization examination revealing oral, pharyngeal, or esophageal candidiasis; * Abnormal liver or kidney function during screening (ALT and/or AST \> 2× upper limit of normal; Scr \> 1.5× upper limit of normal); * Positive hepatitis B surface antigen or hepatitis B core antibody with HBV DNA ≥ 2000 IU/mL, positive hepatitis C antibody with HCV RNA ≥ 1000 IU/mL, positive human immunodeficiency virus antibody, or history of acquired immunodeficiency syndrome; * Known allergy to any component of inhaled corticosteroids or salbutamol preparations; * Respiratory tract infection, sinus infection, or acute otitis media within 4 weeks before screening or during the run-in period, which, in the investigator's judgment, would lead to changes in asthma treatment or affect the subject's asthma status; * Asthma exacerbation requiring systemic corticosteroid treatment within 4 weeks before screening or during the run-in period, or asthma requiring oral corticosteroid therapy, or other conditions requiring systemic corticosteroid treatment; * Use of strong CYP3A4 enzyme inhibitors (e.g., ritonavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, etc.) within 4 weeks before dosing, or need for concomitant use of strong CYP3A4 inhibitors during the trial; * Smoking cessation \< 1 year at screening (including cigarettes, cigars, pipe tobacco, e-cigarettes, etc.), or previous smoking history \> 10 pack-years \[pack-years = number of packs per day × years of smoking, where 1 pack = 20 cigarettes\]; * History of drug abuse, substance abuse, or alcoholism within 2 years before screening \[alcoholism defined as average daily alcohol intake \> 2 units (1 unit = 360 mL beer, or 45 mL of 40% alcohol liquor, or 150 mL wine)\]; * Pregnant or lactating women, or women planning pregnancy during the trial; * Subjects who have participated in other clinical trials within 1 month before screening; * Any other reason considered by the investigator to make the subject unsuitable for participation in the trial.
Conditions Chronic Obstructive Pulmonary Disease (C...
Phase NA
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Comprehensive assessment and interventions to promote adherence to inhaled therapy in patients with bronchial asthma and chronic obstructive pulmonary disease involving health care professionals caring for these patients in different settings and using the Five Steps Assessment tool and artificial intelligence methods and tools.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Education in inhalation technique — Education in inhalation technique

Primary Outcomes

  • Adherence to inhaled treatment measured by Five Steps Assessment (FSA). (Assessment of adherence to inhaled treatment within 12 months.)
  • Adherence to inhaled treatment measured by the Medication Adherence Report Scale (MARS). (Assessment of adherence to inhaled treatment within 12 months.)
  • Critical knowledge measured by our own questionnaire in healthcare professionals caring for patients with COPD and bronchial asthma. (Critical knowledge related to inhalation techniques in healthcare professionals caring for patients with COPD and bronchial asthma within 12 months)
  • Critical skills related to inhalation techniques measured by FSA in healthcare professionals caring for patients with COPD and bronchial asthma. (Critical skills related to inhalation techniques in healthcare professionals caring for patients with COPD and bronchial asthma within 12 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-03
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Charles University, Czech Republic
Collaborators: Ministry of Health, Czech Republic, University Hospital Hradec Kralove, University of Hradec Hralove
Contact Information
Study Contact:
Josef Malý, Assoc. Prof. PhD.
00420 495 067 421
malyj@faf.cuni.cz
Vladimír Koblížek, Prof. PhD.
00420 495 834 771
vladimir.koblizek@fnhk.cz
University Hospital Hradec Králové
Interventions
  • Other: Education in inhalation technique — Education in inhalation technique
Study Locations (1 sites)
University Hospital Hradec Králové, Hradec Králové, 500 05 Czechia
Eligibility Criteria
PATIENTS Inclusion Criteria: 1. signed informed consent, 2. age ≥ 18 years, 3. previously diagnosed BA/COPD meeting GOLD 2024 and GINA 2024 diagnostic criteria, 4. ability to cooperate, 5. at least 8 weeks without exacerbation, 6. use of a particular inhaler for at least 3 months. Exclusion Criteria: 1. pre-terminal/terminal stage of any disease, 2. uncooperative patient, 3. significant limitation of mobility or cognitive functions. HEALTHCARE PROFESSIONALS Inclusion Criteria: 1. signed informed consent, 2. completed education in medicine, pharmacy, or nursing, 3. more than one year of working experience, 4. care for patients taking inhaled therapy for BA/COPD.
Conditions Asthma
Phase PHASE3
Enrollment 34
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age. This study will test how the body processes depemokimab, how the drug works in the body, and its safety and tolerability.

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Depemokimab — Depemokimab will be administered.

Primary Outcomes

  • Depemokimab Concentration in Plasma (Up to Week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-06-25
Completion: 2028-11-24
Eligibility
Age: 6 Years – 11 Years
Sex: ALL
Volunteers: false
Enrollment: 34 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GlaxoSmithKline
Principal Investigators:
  • GSK Clinical Trials (STUDY_DIRECTOR) - GlaxoSmithKline
Contact Information
Study Contact:
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center
+44 (0) 20 89904466
GSKClinicalSupportHD@gsk.com
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
GSK Investigational Site
Interventions
  • Biological: Depemokimab — Depemokimab will be administered.
Study Locations (3 sites)
GSK Investigational Site, Mobile, Alabama 36608 United States
GSK Investigational Site, Colorado Springs, Colorado 80923 United States
GSK Investigational Site, Watertown, South Dakota 13601 United States
Eligibility Criteria
Inclusion Criteria: * Participants who have a documented physician diagnosis of asthma for at least 12 months prior to Visit 1 that meets the National Heart, Lung, and Blood Institute guidelines \[NHLBI, 2007\] or Global Initiative of Asthma (GINA) guidelines \[GINA, 2025\] or Japanese Pediatric Guidelines for The Treatment and Management of Asthma \[JPGL, 2023\] * Asthma with type 2 inflammation characterised by an eosinophilic phenotype as indicated by: elevated peripheral blood eosinophil count of greater than or equal to (\>=)300 cells/microliters (mcL) demonstrated in the past 12 months, or elevated peripheral blood eosinophil count of \>=150 cells/ mcL at visit 1 * Participants who are \>=15 Kilograms (kg) in body weight * A well-documented requirement for regular treatment with inhaled corticosteroid (\>=200 mcg/day fluticasone propionate (DPI) or equivalent daily) in the 12 months prior to Visit 1 with or without maintenance oral corticosteroids (OCS). The Inhaled corticosteroids (ICS) dose should represent medium or high dose in children aged 6-11 years of age * Current treatment with an additional controller medication for at least 3 months prior to screening \[e.g., long-acting beta-2-agonist (LABA), leukotriene receptor antagonist (LTRA), or theophylline\]. For Japan only: This inclusion criterion does not apply to the participants in Japan. As long as the ICS dose represent high dose, the current treatment or previous failure of an additional controller will not be required for eligibility * Previously confirmed history of at least two asthma exacerbations requiring treatment with systemic corticosteroids (CS) (intramuscular \[IM\], intravenous, or oral), in the 12 months prior to visit 1, despite the use of ICS. For participants receiving maintenance OCS, treatment for the exacerbations must have been a two-fold increase or greater in the CS dose * Male or eligible female * A female participant is eligible to participate if she is not pregnant, and one of the following conditions applies: Is prepuberal or having periods but no sexual activity or using an acceptable contraceptive method, if sexual activity. prior to and during the study intervention period (at a minimum until 35 weeks after the last dose of study intervention). * The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a girl with an early undetected pregnancy * The investigator, or a person designated by the investigator, will obtain written informed consent from each study participant and the participant's assent, when applicable, before any study-specific activity is performed unless a waiver of informed consent has been granted by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC). All legal guardians should be fully informed, and participants should be informed to the fullest extent possible, about the study in language and terms they are able to understand * A legal guardian or primary caregiver must be available to help the study-site personnel ensure follow-up; accompany the participant to the study site on each assessment day according to the Schedule of activities (e.g., able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures); consistently and consecutively be available to provide information on the participant, as needed Exclusion Criteria: * Participants with any history of life-threatening asthma (e.g. requiring intubation and assisted ventilation), immunosuppressive medications intake with the exception of oral CS for asthma, or immunodeficiency disorder * Or presence of a known pre-existing, clinically important lung condition other than asthma * Participants with other conditions that could lead to elevated eosinophils * Participants who have known, pre-existing, clinically significant medical conditions that could affect the conduct of the study * Participants with current diagnosis of vasculitis. Participants with high clinical suspicion of vasculitis at screening will be evaluated and current vasculitis excluded prior to enrolment * Participants who have received mepolizumab (Nucala), reslizumab (Cinqair/Cinqaero) or benralizumab (Fasenra) within 130 days or 5-half-lives (whichever is longer) prior to Visit 1 or who have previous documented failure with anti- Interleukin-5 Receptor (IL5/5R) therapy * Participants who have received omalizumab (e.g., Xolair, Omlyclo), tezepelumab (Tezspire) or dupilumab (Dupixent) within 130 days or 5-half-lives (whichever is longer) prior to Visit 1 * Participants who have received any monoclonal Antibody (mAb) within 130 days or 5-half-lives (whichever is longer) of Visit 1. Authorised treatments for Coronavirus disease 2019 (COVID-19) are permitted and should be used in line with local regulatory guidance * Participants who have received treatment with an investigational drug within the past 30 days or 5 terminal phase half-lives of the drug whichever is longer, prior to Visit 1 (this also includes investigational formulations of marketed products) * Participants who have received treatment with an experimental anti-inflammatory drug (non-biologicals) within 3 months prior to Visit 1 * Concurrent enrollment in another clinical trial * Participants with a known, pre-existing parasitic infestation within 6 months prior to Visit 1 * Participants with allergy/intolerance to a mAb or biologic or any of the excipients of the investigational products * Participants who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations * Liver safety exclusion criteria: Participants who meet the following criteria based on results from the sample taken at Screening Visit * Alanine aminotransferase (ALT) greater than (\>)2 \* Upper limit of normal (ULN) * Total bilirubin \>1.5 \* ULN; for participants with Gilbert's syndrome can be included with total bilirubin \>1.5xULN as long as direct bilirubin is less than or equal to (=\<) 1.5 \* ULN * Cirrhosis or current liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice * An abnormal Electrocardiogram (ECG) finding from the 12-lead ECG conducted at Screening, if considered clinically significant and likely to impact the participant's study participation, based on the evaluation of both the investigator and a pediatric cardiologist, or measured results of QT Corrected for Heart Rate using Fridericia's Formula (QTcF) * \>460 milliseconds (msec) * \>480 msec for participants with bundle branch block
Conditions Treatment Resistant Depression
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn about the comparative acute effects of ketamine vs esketamine in participants over the age of 18 for the treatment of their severe depression and suicidal ideations. Participants are already taking antidepressants and/or antipsychotics as part of their regular medical care for depression,

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Drug: Low dose IV Ketamine vs. IN Esketamine — For IV ketamine treatment, ketamine is administered at 0.5mg/kg over 40 minutes. For IN esketamine treatment, esketamine is administered as a nasal spray, two sprays per nostril (56mg total) for the first treatment and three sprays per nostril (84mg) for the rest of the acute series. All treatments are administered at the academic center under the supervision of a mental health care professional. Patients are asked to come fasting at least two hours prior to treatment and to remain resting in the treatment room throughout the dosing session. Throughout each dosing session, blood pressure, oxygen levels, and onset, duration and severity of common side effects are recorded by nursing staff and/or physicians. Patients are discharged after a minimum of 30 minutes post administration, provided that the vital signs return to baseline and that the patient is calm, alert, and oriented.

Primary Outcomes

  • Montgomery-Åsberg Depression Rating Scale (MADRS) (From enrollment to the end of treatment at 4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-03-20
Completion: 2026-10-20
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gustavo Vazquez
Collaborators: Centre for Addiction and Mental Health, Envision Mind Care, Sunnybrook Health Sciences Centre, Djavad Mowafaghian Centre for Brain Health
Principal Investigators:
  • Gustavo H Vazquez, MD,PhD,FRCPC (PRINCIPAL_INVESTIGATOR) - Queen&#39;s University
Contact Information
Study Contact:
Gustavo H Vazquez, MD,PhD,FRCPC
+1 (613)-544-4900
g.vazquez@queensu.ca
Gustavo H Vazquez, MD,PhD,FRCPC
613-544-4900
g.vazquez@queensu.ca
Providence Care Hospital
Interventions
  • Drug: Low dose IV Ketamine vs. IN Esketamine — For IV ketamine treatment, ketamine is administered at 0.5mg/kg over 40 minutes. For IN esketamine treatment, esketamine is administered as a nasal spray, two sprays per nostril (56mg total) for the first treatment and three sprays per nostril (84mg) for the rest of the acute series. All treatments are administered at the academic center under the supervision of a mental health care professional. Patients are asked to come fasting at least two hours prior to treatment and to remain resting in the treatment room throughout the dosing session. Throughout each dosing session, blood pressure, oxygen levels, and onset, duration and severity of common side effects are recorded by nursing staff and/or physicians. Patients are discharged after a minimum of 30 minutes post administration, provided that the vital signs return to baseline and that the patient is calm, alert, and oriented.
Study Locations (1 sites)
Providence Care Hospital, Kingston, Ontario K7L4X3 Canada
Eligibility Criteria
Inclusion Criteria: * Adult outpatients (18-75 years old) with unipolar depression experiencing major depressive episodes as determined by the DSM5 and characterized as MDD-TRD (diagnosed with major depressive disorder as outlined by the DSM5) and experienced at least two previous failed antidepressant treatments of adequate dose and duration for the current episode Exclusion Criteria: * Individuals with psychosis, main diagnosis of personality disorder, uncontrolled hypertension, substance abuse, currently pregnant or breastfeeding, or who had a previous negative reaction to ketamine or esketamine, were ineligible to receive IV ketamine or IN esketamine.
Conditions Depressive Disorder, Major
Phase NA
Enrollment 64
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The present study investigates the effect of Mediterranean Diet and Mindful Eating on depression severity in people with obesity and major depressive disorder. The factorial design allows to investigate potential synergistic effects of the interventions. Participants will be randomized to one of the four intervention groups (mediterranean diet, mindful eating, their combination and a befriending control group). The intervention consists of a 12-week period, followed by a 12-week follow up. The primary outcome is depression severity.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: nutritional intervention — nutritional intervention to mediterranean diet
  • Behavioral: Mindful Eating — intervention regarding mindful eating, e.g. attention while eating, apprechiation of food
  • Other: Attention Control — Befreinding Control Group: Provision of same amout of time and attention, without having an intervention, e.g. talking about hobbies and interests, playing card games

Primary Outcomes

  • Depression severity (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-05
Completion: 2025-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital Tuebingen
Collaborators: Robert Bosch Center for Integrative Medicine and Health, Department of Psychosomatic Medicine, Robert Bosch Hospital Stuttgart, Microbial Genetics, Interfaculty Institute of Microbiology and Infection Medicine Tübingen, University of Tübingen
Contact Information
Study Contact:
Alina Moosburner, MSc
+4971181013764
alina.moosburner@med.uni-tuebingen.de
Holger Cramer, Prof. Dr.
holger.cramer@med.uni-tuebingen.de
Alina Moosburner
071181013764
alina.moosburner@med.uni-tuebingen.de
Robert Bosch Center for Integrative Medicine and Health
Interventions
  • Other: nutritional intervention — nutritional intervention to mediterranean diet
  • Behavioral: Mindful Eating — intervention regarding mindful eating, e.g. attention while eating, apprechiation of food
  • Other: Attention Control — Befreinding Control Group: Provision of same amout of time and attention, without having an intervention, e.g. talking about hobbies and interests, playing card games
Study Locations (1 sites)
Robert Bosch Center for Integrative Medicine and Health, Stuttgart, 70376 Germany
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Presence of clinically diagnosed major depression * At least moderate depression severity: BDI-II ≥ 20 * obesity: BMI ≥ 30 kg/m2 * Stable co-intervention: no change in the type, dosage or frequency of antidepressant medication and/or psychotherapy four weeks before and during the study * Low adherence to the mediterranean diet: MEDAS \< 10 * Low adherence to mindful eating: MEI \< 5.13 Exclusion Criteria: * Diseases of the gastrointestinal tract that do not allow adequate implementation of the intervention (e.g. irritable bowel syndrome, post-bariatric surgery, colorectal carcinoma) * Metabolic diseases with strong impact on intervention (e.g. type 1 diabetes mellitus, chronic kidney disease) * Severe food allergies and intolerances, that do not allow adequate implementation of the intervention * Diagnosed, current psychological comorbidities (bipolar disorder, eating disorder, personality disorder, psychosis) * intake of antibiotics in the last three months current substance abuse * Pregnancy and breatfeeding * Suicidal ideation * unable to participate or complete questionnaires Healthy Volunteers: samples of 32 healthy volunteers are included for microbiome analysis only ( inclusion criteria: * age ≥ 18 years * BMI 20 - 30 kg/m\^2 exclusion criteria: * depression or other psychological comorbidities (bipolar disorder, eating disorder, personality disorder, psychosis) * high adhernece to mediterranean diet: MEDAS ≥ 10 * high adherence to mindful eating: MEI ≥ 5.13 * Diseases of the gastrointestinal tract or metabilic diseases (e.g. irritable bowel syndrome, post-bariatric surgery, colorectal carcinoma, type 1 diabetes mellitus) \-- intake of antibiotics in the last three months current substance abuse * pregnancy or breastfeeding